drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Chimeric IgG1 anti-CD20 monoclonal antibody that binds CD20 on B cells (pre-B to mature, not plasma cells) and depletes them via ADCC, CDC, and apoptosis; reduces B-cell antigen presentation, proinflammatory cytokines, and autoantibody activity. Used off-label in MS.
nci_thesaurus_concept_id
C1702
nci_thesaurus_preferred_term
Rituximab
nci_thesaurus_definition
A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)
drug_mesh_term
Rituximab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Cytotoxic protein
drug_delivery_route
Intravenous
drug_mechanism_of_action
Chimeric IgG1 monoclonal antibody against CD20 on pre-B to mature B cells (not plasma cells); depletes CD20+ B cells via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis, reducing B-cell antigen presentation, proinflammatory cytokines, and autoantibody activity.
drug_name
Rituximab
nct_id_drug_ref
NCT05758831